Program
KAT6/KAT7 Inhibitor IDE574
Its studies are mostly in Neoplasms, led by IDEAYA Biosciences.
Furthest: phase 1, since Apr 1, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| IDEAYA Biosciences | 11 open or running | phase 1since Apr 1, 2026 | Apr 1, 2026 | Dec 31, 2029phase 1 · NCT07540572 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 1, 2026First study: phase 1 study in NeoplasmsFirst studyNCT07540572 · 155 planned · United States, Georgia
Ahead
- Dec 31, 2029Primary completion: phase 1 study in NeoplasmsNCT07540572
TargetBeta
“An orally bioavailable small molecule inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3), KAT6B (MORF; MOZ2; MYST4) and KAT7 (HBO1; MYST2), ”NCIt, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540572Neoplasms · United States, Georgia | 1 | Recruiting | Dec 31, 2029 | 155 |
How it is read
Names in the registry
- “IDE574”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.